Incidence and risk factors of coronary artery disease in patients on chronic hemodialysis

International Journal of Artificial Organs

Volumn 30, Issue 3, 2007, Pages 253-257

  Soubassi, L P ^a   Papadakis, E D ^a   Theodoropoulos, I K ^a   Poulos, G D ^a   Chaniotis, D I ^a   Tsapakidis, I P ^a   Zerefos, Stelios N ^a,b   Douli, M ^a   Chiras, Th Ch ^a   Kouvelis, A ^a   Daglas, G K ^a   Soubassi, S P ^a   Valis, D N ^a  

^a HYGEIA HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Chronic hemodialysis; Coronary artery disease; Incidence; Risk factors

Indexed keywords

DIALYSIS; HEART; HEMODIALYZERS; NUTRITION; REGRESSION ANALYSIS;

BODY MASS; CHRONIC HEMODIALYSIS; CORONARY ARTERY DISEASE; CORONARY HEART DISEASE; HAEMODIALYSIS; HOMOCYSTEINES; INCIDENCE; MASS INDEX; RELATIVE RISKS; RISK FACTORS;

DISEASES;

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEMOGLOBIN; HOMOCYSTEINE; NITRATE; SALICYLIC ACID DERIVATIVE; THALLIUM;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ANEMIA; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; EXERCISE TEST; FEMALE; HEART SCINTISCANNING; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOALBUMINEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LINEAR REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBESITY; PHARMACOLOGIC STRESS TESTING; PROTEIN BLOOD LEVEL; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; SMOKING HABIT; STATISTICAL SIGNIFICANCE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION;

EID: 34248342728     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000311     Document Type: Article

References (24)

1. Murphy SW, Foley RN, Parfrey PS, et al. Screening and treatment for cardiovascular disease in patients with chronic renal disease. Am J Kidney Dis 1998; 32 (suppl): S184-99.
2. Massy ZA. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant 2000; 15: 81-91.
3. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-9.
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
5. Foley RN, Parfrey PS, Sarnak MJ, et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (suppl): S112-9.
6. Parfrey PS. Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000; 15: 58-68.
7. Schimidt A, Stefenelli Th, Schnster E, Mayer G. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 2001; 37: 56-63.
8. US Preventive Services Task Force. Guide to Clinical Preventive Services (cd 2). Baltimore, MD: Williams and Williams; 1996.
9. Kasiske BL, Ramos EL, Gaston RS, et al. The evaluation of renal transplant candidates: Clinical practice guidelines. J Am Soc Nephrol 1995; 6: 3431-9.
10. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
11. Herzog CA, Ma JZ, Collins AJ, et al. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207-11.
12. Rostand SG, Kirk KA, Rutsky EA, et al. Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 1984; 25: 653-9.
13. London GM, Parfrey PS. Cardiac disease in chronic uremia: Pathogenesis. Adv Ren Replace Ther 1997; 4: 194-211.
14. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-62.
15. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-27.
16. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-14.
17. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
18. Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant 2002; 17: 10-5.
19. Seyrek N, Balal M, Karayaylali I, et al. Which parameter is more influential on the development of arteriosclerosis in hemodialysis patients? Ren Fail 2003; 25: 1011-8.
20. Dahan M, Viron BM, Faraggi M, et al. Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int 1998; 54: 255-62.
21. Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: A meta-analysis. J Am Soc Nephrol 2003; 14: 431-9.
22. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001; 37: 1191-200.
23. Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up. J Am Soc Nephrol 1999; 10: 1027-36.
24. Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation 2002; 106: 2812-8.